V. Westeel

523 total citations
20 papers, 334 citations indexed

About

V. Westeel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, V. Westeel has authored 20 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in V. Westeel's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Lung Cancer Research Studies (5 papers). V. Westeel is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Lung Cancer Research Studies (5 papers). V. Westeel collaborates with scholars based in France, China and Canada. V. Westeel's co-authors include B. Milleron, Élisabeth Quoix, Jean-Luc Breton, Jean-Louis Pujol, Xavier Quantin, Jean Pierre Daurès, M. Poudenx, Aart Brutel de la Rivière, D. Del Moro and É. Lemarié and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

V. Westeel

19 papers receiving 311 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. Westeel France	8	262	205	114	85	18	20	334
J.R. Fischer Germany	9	247 0.9×	191 0.9×	75 0.7×	78 0.9×	10 0.6×	20	300
Akihisa Fujita Japan	10	275 1.0×	227 1.1×	77 0.7×	159 1.9×	4 0.2×	27	386
Marshall Posner United States	6	126 0.5×	123 0.6×	36 0.3×	68 0.8×	4 0.2×	13	327
Chiharu Tanai Japan	11	140 0.5×	269 1.3×	30 0.3×	90 1.1×	27 1.5×	21	404
Kathleen M. Aguilar United States	9	97 0.4×	78 0.4×	99 0.9×	31 0.4×	6 0.3×	36	307
Josiane Mourão Dias Brazil	7	86 0.3×	99 0.5×	37 0.3×	38 0.4×	6 0.3×	19	205
Jim Ranger‐Moore United States	8	151 0.6×	60 0.3×	58 0.5×	56 0.7×	4 0.2×	13	238
Kim Norris United States	3	219 0.8×	100 0.5×	182 1.6×	55 0.6×	6 0.3×	8	249
O Campobasso Italy	7	151 0.6×	82 0.4×	111 1.0×	49 0.6×	10 0.6×	11	230
S. Morris Switzerland	7	243 0.9×	123 0.6×	93 0.8×	53 0.6×	3 0.2×	13	267

Countries citing papers authored by V. Westeel

Since Specialization

Citations

This map shows the geographic impact of V. Westeel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Westeel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Westeel more than expected).

Fields of papers citing papers by V. Westeel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Westeel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Westeel. The network helps show where V. Westeel may publish in the future.

Co-authorship network of co-authors of V. Westeel

This figure shows the co-authorship network connecting the top 25 collaborators of V. Westeel. A scholar is included among the top collaborators of V. Westeel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Westeel. V. Westeel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tosato, Giovanna, Yuna Blum, Alexandra Langlais, et al.. (2025). 239MO: Stratification of pleural mesothelioma patients for combined immunotherapy based on sarcomatoid component and tumour microenvironment markers in the IFCT-MAPS2 study. Journal of Thoracic Oncology. 20(3). S151–S151. 1 indexed citations

Wislez, Marie, Céline Mascaux, Jacques Cadranel, et al.. (2023). 1400P Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study. Annals of Oncology. 34. S801–S802. 2 indexed citations

Girard, Nicolas, Laurent Greillier, Gérard Zalcman, et al.. (2020). Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. Respiratory Medicine and Research. 78. 100769–100769. 10 indexed citations

Westeel, V.. (2018). MS17.03 Surveillance and Second Primary Malignancies in Lung Cancer Survivors. Journal of Thoracic Oncology. 13(10). S277–S278. 2 indexed citations

Cadranel, Jacques, Élisabeth Quoix, M. Duruisseaux, et al.. (2015). 3128 EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort. European Journal of Cancer. 51. S646–S646. 1 indexed citations

Manzoni, P., P. Jacoulet, D. Pernet, et al.. (2011). [Bevacizumab and lung cancer: eligible patients in daily practice].. Translational Oncology. 28(1). 25–31. 2 indexed citations

Mascaux, Céline, Guénaëlle Levallet, Emmanuel Bergot, et al.. (2011). Use of a three-microRNA signature to discriminate prognostic groups in early-stage NSCLC patients in the IFCT-0002 trial.. Journal of Clinical Oncology. 29(15_suppl). 7007–7007. 2 indexed citations

Cadranel, Jacques, R. Gervais, Marie Wislez, et al.. (2011). IFCT-0504 trial: Mucinous (M) and nonmucinous (NM) cytologic subtypes interaction effect in first-line treatment of advanced bronchioloalveolar carcinoma (BAC) by erlotinib (E) or carboplatin/paclitaxel (C/P).. Journal of Clinical Oncology. 29(15_suppl). 7521–7521. 1 indexed citations

Westeel, V., B. Milleron, Élisabeth Quoix, et al.. (2010). Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer.. Journal of Clinical Oncology. 28(15_suppl). 7003–7003. 8 indexed citations

10.

Pérol, M., C. Chouaïd, B. Milleron, et al.. (2010). Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.. Journal of Clinical Oncology. 28(15_suppl). 7507–7507. 71 indexed citations

11.

Quoix, Élisabeth, V. Westeel, Éric Pichon, et al.. (2010). Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(18_suppl). 2–2. 46 indexed citations

12.

Morère, Jean‐François, V. Westeel, Franck Morin, et al.. (2008). Randomized phase II trial of first-line gefitinib, gemcitabine or docetaxel in performance status (PS) 2 or 3 non-small-cell lung cancer (NSCLC) patients (IFCT-0301). Journal of Clinical Oncology. 26(15_suppl). 8086–8086. 2 indexed citations

13.

Ramlau, Rodryg, V. Westeel, Zsolt Pápai, et al.. (2008). Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 8023–8023. 11 indexed citations

14.

Milleron, B., Élisabeth Quoix, V. Westeel, et al.. (2007). IFCT0002 phase III study comparing a preoperative (PRE) and a perioperative (PERI) chemotherapy with two different CT regimens in resectable non-small cell lung cancer (NSCLC): Early results. Journal of Clinical Oncology. 25(18_suppl). 7519–7519. 2 indexed citations

15.

Depierre, A & V. Westeel. (2007). [Preoperative chemotherapy in non-small cell lung cancer: advantages, disadvantages, level of evidence].. PubMed. 24(8 Pt 2). 6S59–63. 2 indexed citations

16.

Pujol, Jean-Louis, Jean Pierre Daurès, Aart Brutel de la Rivière, et al.. (2001). Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study. JNCI Journal of the National Cancer Institute. 93(4). 300–308. 111 indexed citations

17.

Westeel, V., et al.. (2000). [A misleading form of hypersensitivity pneumonitis].. PubMed. 17(5). 987–9. 1 indexed citations

18.

Westeel, V., Nevin Murray, Karen A. Gelmon, et al.. (1998). New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen.. Journal of Clinical Oncology. 16(5). 1940–1947. 42 indexed citations

19.

Westeel, V., A. Dubiez, V. Meyer, et al.. (1998). [Respective influence of occupational and personal factors on respiratory function in dairy farmers].. PubMed. 15(6). 765–72. 13 indexed citations

20.

Jacoulet, P., A. Dubiez, V. Westeel, et al.. (1997). [Second line chemotherapy in patients with refractory and resistant non small cell lung cancer].. PubMed. 14(1). 29–35. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact